Jennifer Humes compensation by year
Roivant Sciences Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $41,897 |
| Bonus | $281,450 |
| Stock awards | $1,231,437 |
| Option awards | $826,878 |
| All other | $1,293 |
| Total | $2,382,956 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Roivant Sciences Ltd. DEF 14A filed July 29, 2025, accession 0001140361-25-027846, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 112,255 | $1,132,653 | — |
| Option | 115,108 | — | $10.97 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Roivant Sciences Ltd.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2024 proxy (filed July 29, 2025)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-20 | Tax withholding | — | 3,880 | $39.77 | 106,419 |
| 2026-06-20 | Tax withholding | — | 3,582 | $31.43 | 109,782 |
| 2026-04-20 | Grant or award derivative | — | 27,157 | $0.00 | 27,157 |
| 2026-04-20 | Grant or award | — | 29,173 | $0.00 | 113,364 |
| 2026-04-08 | Sale | — | 13,538 | $28.37 | 84,191 |
| 2026-03-20 | Tax withholding | — | 14,526 | $27.70 | 97,729 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Roivant Sciences discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Death | $0 | $0 | $0 | $0 |
| Disability | $0 | $0 | $0 | $0 |
| Involuntary termination without cause | $0 | $0 | $0 | $0 |
| Change in control and involuntary termination | $0 | $1,132,653 | $0 | $1,132,653 |
Per the Potential Payments Upon Termination or Change in Control table in Roivant Sciences Ltd.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Roivant Sciences’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Mayukh Sukhatme | President and Chief Investment Officer | $251,858,764 |
| Matthew Gline | Chief Executive Officer | $163,293,744 |
| Eric Venker | President and Immunovant CEO | $11,807,422 |
| Rakhi Kumar | Former Chief Accounting Officer | $4,693,938 |
| Richard Pulik | Chief Financial Officer | $4,127,151 |
| Jennifer Humes · this page | Chief Accounting Officer | $2,382,956 |
The full Roivant Sciences compensation record
free company briefThis page is one person within Roivant Sciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Roivant Sciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Roivant Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat